Skip to main content

Autolus Therapeutics plc 8-K, filed Nov 10, 2026

Autolus Therapeutics plc (AUTL)

8-K 2026-11-10 For: 2026-11-10
View Original
Added on November 10, 2026

About this 8-K

Autolus Therapeutics plc filed this 8-K on November 10, 2026.

Autolus Therapeutics plc reported third-quarter AUCATZYL net product revenue of $41.2 million, up 95% year-over-year, and now expects 2026 revenue at or exceeding the upper end of $150 million. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 7.01: Regulation FD disclosure
  • Item 9.01: Financial statements and exhibits